These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 34846525)

  • 1. Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.
    Li N; Zhu Y; Liu LY; Feng YR; Wang WL; Wang J; Wang H; Li GF; Tang Y; Hu C; Liu WY; Ren H; Wang SL; Wang WH; Song YW; Liu YP; Fang H; Tang Y; Lu NN; Chen B; Qi SN; Liu XF; Li YX; Jin J
    JAMA Netw Open; 2021 Nov; 4(11):e2136116. PubMed ID: 34846525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
    Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
    Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
    Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.
    Feng YR; Zhu Y; Liu LY; Wang WH; Wang SL; Song YW; Wang X; Tang Y; Liu YP; Ren H; Fang H; Zhang SP; Liu XF; Yu ZH; Li YX; Jin J
    Oncotarget; 2016 May; 7(18):25576-84. PubMed ID: 27014909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
    Yang B; Shan J; Feng Y; Dai N; Li M; Chen C; He S; Wang G; Xiao H; Li C; Wang D
    Radiat Oncol; 2020 May; 15(1):94. PubMed ID: 32375814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
    Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y
    BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
    JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.
    Lund JL; Sturmer T; Sanoff HK
    J Geriatr Oncol; 2016 May; 7(3):176-86. PubMed ID: 26926829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).
    Jin J; Tang Y; Hu C; Jiang LM; Jiang J; Li N; Liu WY; Chen SL; Li S; Lu NN; Cai Y; Li YH; Zhu Y; Cheng GH; Zhang HY; Wang X; Zhu SY; Wang J; Li GF; Yang JL; Zhang K; Chi Y; Yang L; Zhou HT; Zhou AP; Zou SM; Fang H; Wang SL; Zhang HZ; Wang XS; Wei LC; Wang WL; Liu SX; Gao YH; Li YX
    J Clin Oncol; 2022 May; 40(15):1681-1692. PubMed ID: 35263150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
    Glynne-Jones R; Counsell N; Quirke P; Mortensen N; Maraveyas A; Meadows HM; Ledermann J; Sebag-Montefiore D
    Ann Oncol; 2014 Jul; 25(7):1356-1362. PubMed ID: 24718885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
    Garcia-Aguilar J; Patil S; Gollub MJ; Kim JK; Yuval JB; Thompson HM; Verheij FS; Omer DM; Lee M; Dunne RF; Marcet J; Cataldo P; Polite B; Herzig DO; Liska D; Oommen S; Friel CM; Ternent C; Coveler AL; Hunt S; Gregory A; Varma MG; Bello BL; Carmichael JC; Krauss J; Gleisner A; Paty PB; Weiser MR; Nash GM; Pappou E; Guillem JG; Temple L; Wei IH; Widmar M; Lin S; Segal NH; Cercek A; Yaeger R; Smith JJ; Goodman KA; Wu AJ; Saltz LB
    J Clin Oncol; 2022 Aug; 40(23):2546-2556. PubMed ID: 35483010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
    Feng YR; Jin J; Ren H; Wang X; Wang SL; Wang WH; Song YW; Liu YP; Tang Y; Li N; Liu XF; Fang H; Yu ZH; Li YX
    BMC Cancer; 2017 Mar; 17(1):182. PubMed ID: 28279170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
    Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
    JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
    O'Connell MJ; Colangelo LH; Beart RW; Petrelli NJ; Allegra CJ; Sharif S; Pitot HC; Shields AF; Landry JC; Ryan DP; Parda DS; Mohiuddin M; Arora A; Evans LS; Bahary N; Soori GS; Eakle J; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Wozniak TF; Roh MS; Yothers G; Wolmark N
    J Clin Oncol; 2014 Jun; 32(18):1927-34. PubMed ID: 24799484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
    Rahma OE; Yothers G; Hong TS; Russell MM; You YN; Parker W; Jacobs SA; Colangelo LH; Lucas PC; Gollub MJ; Hall WA; Kachnic LA; Vijayvergia N; O'Rourke MA; Faller BA; Valicenti RK; Schefter TE; George S; Kainthla R; Stella PJ; Sigurdson E; Wolmark N; George TJ
    JAMA Oncol; 2021 Aug; 7(8):1225-1230. PubMed ID: 34196693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.